Back to top
more

Stryker (SYK)

(Real Time Quote from BATS)

$339.67 USD

339.67
1,481,458

-0.75 (-0.22%)

Updated Jul 25, 2024 09:36 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval

Inspire Medical's (INSP) receipt of the latest CE mark certification will likely enable it to continue to deliver Inspire products globally.

Catalent (CTLT) Expands Its Facility Capabilities in Germany

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.

Stryker (SYK) Completes Artelon's Acquisition to Boost Business

Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.

DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?

DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Patterson Companies (PDCO) Aims to Streamline Patient Experience

Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.

Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis

Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.

Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are a concern.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark

Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.

GE HealthCare's (GEHC) New Solution to Aid Prostate Treatment

GE HealthCare's (GEHC) MIM Software introduced the MIM Symphony HDR Prostate to provide direct tumor visualization using MRI images during live ultrasound procedures for HDR prostate treatments.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Microbot Medical (MBOT) Progresses in Its Human Clinical Trial

Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.

3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit

Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.

EYE or SYK: Which Is the Better Value Stock Right Now?

EYE vs. SYK: Which Stock Is the Better Value Option?

Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?

Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.

Three Reasons to Hold BD (BDX) Stock in Your Portfolio Now

BD's (BDX) robust product portfolio raises optimism about the stock.

Merit Medical (MMSI) Inks Deal to Boost Endoscopy Portfolio

Merit Medical's (MMSI) latest asset acquisition is likely to expand its endoscopy portfolio with a minimally-invasive solution for GERD patients, thereby improving patient outcomes.

Here's Why You Should Retain Ensign Group (ENSG) Stock Now

Ensign Group (ENSG) remains well-poised for growth on the back of solid segmental contributions, an expanding healthcare portfolio and sound cash reserves.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.

The Zacks Analyst Blog Highlights NIKE, Stryker and TJX

NIKE, Stryker and TJX are included in this Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for NIKE, Stryker & TJX

Today's Research Daily features new research reports on 16 major stocks, including NIKE, Inc. (NKE), Stryker Corporation (SYK) and The TJX Companies, Inc. (TJX).

Why Is QuidelOrtho (QDEL) Down 2.4% Since Last Earnings Report?

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System

Stryker (SYK) announces the launch of LIFEPAK 35 monitor/defibrillator, which is likely to aid emergency responders to reduce cognitive load during demanding situations by improving workflow.

Stryker's (SYK) Acquisition of Artelon Set to Expand Its Market

Stryker (SYK) announces the signing of the definitive agreement to acquire a privately held company, Artelon, to strengthen its foothold in the soft tissue fixation market.